ALung Technologies closes $36 million financing

Investment led by Philips and UPMC to fund pivotal trial of artificial lung technology. PITTSBURGH (April 11, 2017) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the closing of a $36 million Series C financing, including existing convertible notes. (read more)

ALung poised for sales in Germany

3 February 2012 Investment News, Recent News

Investors satisfaction leads to $10 million of additional fundraising as ALung prepares to enter the European medical device market. (read more)